Skip to main content

Table 3 Estimated relative risk (odds ratio) of exhibiting metabolic syndrome components associated with the SST poly-T repeat polymorphism genotype

From: Association study between a polymorphic poly-T repeat sequence in the promoter of the somatostatin gene and metabolic syndrome

  Genotypes   Abdominal
Obesity
Hypertriglyceridemia Low HDL-Cholesterol Hypertension Hyperglycaemia Metabolic
Syndrome
Entire samplea 13/13 p=
OR
1 1 1 1 1 1
13/14 OR 1.46 1.24 0.96 0.66 1.68 1.10
p-value
95%CI
0.18
(0.84–2.53)
0.39
(0.76–2.04)
0.87
(0.59–1.57)
0.18
(0.36–1.21)
0.05
(1.01–2.81)
0.71
(0.66–1.83)
13/15 OR 1.07 1.24 1.02 1.26 1.07 1.13
p-value
95%CI
0.57
(0.85–1.34)
0.05
(1.01–1.53)
0.85
(0.83–1.26)
0.05
(1.00–1.59)
0.53
(0.86–1.34)
0.28
(0.91–1.40)
13/16 OR 1.60 1.55 1.55 1.48 1.43 1.79
p-value
95%CI
0.01
(1.10–2.33)
0.01
(1.11–2.17)
0.01
(1.11–2.17)
0.03
(1.04–2.11)
0.04
(1.02–2.02)
<  0.01
(1.27–2.53)
Menb 13/13 OR 1 1 1 1 1 1
13/14 OR 0.99 1.49 0.79 0.55 1.71 0.85
p-value
95%CI
0.98
(0.46–2.12)
0.25
(0.75–2.96)
0.50
(0.41–1.54)
0.15
(0.24–1.25)
0.12
(0.87–3.37)
0.64
(0.66–1.83)
13/15 OR 0.91 1.32 1.03 1.09 0.99 1.00
p-value
95%CI
0.58
(0.65–1.27)
0.07
(0.98–1.78)
0.84
(0.77–1.39)
0.59
(0.79–1.50)
0.96
(0.73–1.34)
1.00
(0.91–1.40)
13/16 OR 1.43 1.93 1.68 1.08 1.26 1.50
p-value
95%CI
0.20
(0.83–2.47)
0.01
(1.22–3.07)
0.03
(1.06–2.65)
0.75
(0.68–1.72)
0.31
(0.81–1.96)
0.08
(0.95–2.37)
Womenb 13/13 OR 1 1 1 1 1 1
13/14 OR 2.08 1.04 1.21 0.86 1.66 1.59
p-value
95%CI
0.06
(0.98–4.42)
0.91
(0.49–2.21)
0.61
(0.58–2.52)
0.74
(0.35–2.11)
0.21
(0.75–3.67)
0.24
(0.74–3.43)
13/15 OR 1.22 1.12 1.01 1.45 1.17 1.26
p-value
95%CI
0.21
(0.89–1.66)
0.49
(0.82–1.52)
0.94
(0.75–1.37)
0.03
(1.03–2.04)
0.35
(0.84–1.64)
0.16
(0.91–1.73)
13/16 OR 1.77 1.19 1.41 2.33 1.73 2.25
p-value
95%CI
0.03
(1.06–2.95)
0.51
(0.72–1.98)
0.18
(0.86–2.32)
<  0.01
(1.33–4.09)
0.04
(1.02–2.93)
< 0.01
(1.33–3.79)
  1. aIncluding age and sex as covariates
  2. bIncluding age as a covariate
  3. Significant p-values were italicized